Publications by authors named "Hadar Amir-Barak"
Achalasia is a disorder of esophageal motility characterized by absent relaxation of the lower esophageal sphincter and abnormal peristalsis of the esophagus during swallowing. The etiology is divided into primary idiopathic achalasia and secondary achalasia and classified into 3 subtypes based on manometric evaluation, according to the Chicago 4.0 classification.
View Article and Find Full Text PDFBackground And Aims: Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the effectiveness of biologic early prophylaxis for preventing endoscopic post-operative recurrence (ePOR) in Crohn's disease patients after ileocecal resection (ICR).
- It included 297 patients and found that ePOR occurred in about 41.8% of cases within one year, with varying rates across treatment groups: 40.2% for anti-TNF, 33% for vedolizumab (VDZ), and 61.8% for ustekinumab (UST).
- The results indicated no significant differences in ePOR risk between the anti-TNF therapy and the other biologics after adjusting for patient factors, suggesting early prevention was effective for around 60% of patients regardless of
Background And Aims: Skin eruptions are prevalent among patients with inflammatory bowel diseases (IBD), often associated with therapies and frequently leading to dermatological consults and treatment interruptions. We aimed to assess the impact of joint shared decision-making in a multidisciplinary (MDT) IBD-DERMA clinic.
Methods: This retrospective cohort study assessed a consecutive group of patients with IBD who were referred for consultation in an MDT clinic at a tertiary referral center in Israel.
Article Synopsis
- This study looked into how well two medications, ustekinumab (UST) and vedolizumab (VDZ), work as third-line treatments for patients with Crohn's disease who haven’t responded well to other medications.
- Researchers included 204 patients, with 76% receiving VDZ followed by UST, and 24% the opposite. After 16 to 22 weeks, about half of patients in both groups showed a response to the treatment.
- By week 52, similar response rates (around 86%) were observed, with about a quarter to a third of patients attaining clinical remission, indicating that both medications were similarly effective as third-class therapies. *
Goal: The aim was to assess proactive specialized inflammatory bowel diseases (IBD) emergency department (ED) consultation and multidisciplinary IBD team (IBD-MDT) intervention on IBD-related patient outcomes after discharge.
Background: Despite advances in patient care, IBD-related ED visits have increased and substantially contribute to the IBD burden.
Methods: Consecutive patients with IBD (below 50 y) who visited the ED during November 2017 to April 2018 (intervention group) were compared with patients with IBD that visited the same ED during 2014 to 2017 (standard-care group).
Low Risk of Neoplasia and Intraprocedural Adverse Events in Gastric Hyperplastic Polypectomy.
J Clin Gastroenterol
October 2021
Goals: Assess neoplasia and polypectomy-related adverse event (AE) rates in gastric hyperplastic polyps (GHPs).
Background: GHPs carry a risk of neoplastic transformation. The rate of neoplastic transformation and the risk of polypectomy-related bleeding are unclear in the West, as data are derived from Asian or small studies.
Pulsed electromagnetic fields (PEMFs) have been considered a potential treatment modality for fracture healing, however, the mechanism of their action remains unclear. Mammalian target of rapamycin (mTOR) signaling may affect osteoblast proliferation and differentiation. This study aimed to assess the osteogenic differentiation of mesenchymal stem cells (MSCs) under PEMF stimulation and the potential involvement of mTOR signaling pathway in this process.
View Article and Find Full Text PDF